— 30% Sales Increase Drove Significant Profit Growth —
— Order Rates Increased 30% —
— Guiding to Fiscal Fourth Quarter Sales Growth of 25% at the Midpoint —
— Guiding to Further Gross Margin Improvement Led by Volumes and Pricing —
— Pathway to Robust FY23 Revenue and Profit Growth —
Selected Financial Highlights:
Third Quarter FY 2022
- Net sales of
$180.9 million , up 30% year-over-year - Gross margin expanded 180 basis points to 30.5%
- Net income of
$6.3 million ; Adjusted net income of$7.6 million - Diluted EPS of
$0.17 ; Adjusted diluted EPS was$0.21 - Adjusted EBITDA of
$11.5 million - Backlog of
$178.5 million
Management Commentary
CEO
“Kimball International continues to compete successfully in the evolving domestic commercial furniture marketplace, as our ancillary product lines and key secondary geographies are well aligned with the new-forming workplace. Ancillary products, which accounted for 86% of our trailing 12 months sales are perfectly suited for employers prioritizing collaboration and engagement in both hybrid and in-person settings. Shipments to smaller metropolitan areas, which have benefited from significant population growth in recent years, represented 77% of our trailing 12 months sales.
“These differentiators continue to result in substantial sales growth in our Workplace and Health markets, supporting our confidence that
Overview
Third Quarter Fiscal 2022 Results
Consolidated net sales increased 30% to
Three Months Ended | Nine Months Ended | ||||||||||||||||
(Unaudited) | |||||||||||||||||
(Amounts in Millions) | 2022 | 2021 | % Change | 2022 | 2021 | % Change | |||||||||||
Workplace * | $ | 119.8 | $ | 78.9 | 52 | % | $ | 336.3 | $ | 261.6 | 29 | % | |||||
Health | 26.6 | 24.6 | 8 | % | 76.2 | 72.2 | 6 | % | |||||||||
Hospitality | 34.5 | 35.2 | (2 | %) | 76.4 | 89.0 | (14 | %) | |||||||||
Total |
$ | 180.9 | $ | 138.7 | 30 | % | $ | 488.9 | $ | 422.8 | 16 | % |
Orders Received by End Market | |||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||
(Unaudited) | |||||||||||||||||
(Amounts in Millions) | 2022 | 2021 | % Change | 2022 | 2021 | % Change | |||||||||||
Workplace * | $ | 121.0 | $ | 88.7 | 36 | % | $ | 377.8 | $ | 255.3 | 48 | % | |||||
Health | 26.8 | 26.2 | 2 | % | 86.5 | 75.9 | 14 | % | |||||||||
Hospitality | 17.5 | 12.2 | 43 | % | 68.4 | 70.7 | (3 | %) | |||||||||
Total Orders | $ | 165.3 | $ | 127.1 | 30 | % | $ | 532.7 | $ | 401.9 | 33 | % |
* Workplace end market includes education, government, commercial, and financial vertical markets and eBusiness
Summary and Outlook
“Third quarter results and order rates firmly position us to achieve our revenue guidance for 2022 with a significant improvement in profitability. We expect positive demand trends to continue into fiscal 2023, given the relevance of our product designs to collaboration and culture-building. With a portfolio tailored to the growing Workplace and Health end markets, our increased traction in eCommerce and our presence in expanding geographies,
“Additionally, we believe we reached an inflection point at the end of the third quarter and expect fourth quarter benefits from higher volumes and pricing to outpace inflationary pressures, resulting in considerable sequential expansion in gross margin. S&A spending will continue to reflect our investments in future growth but is expected to decline further as a percentage of sales in fiscal 2023,”
Fourth Quarter FY 2022 Guidance Ranges | ||||
Low | High | |||
Revenue | ||||
Gross margin | 31.5% | 32.5% | ||
Adjusted S&A |
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. A non-GAAP financial measure is a numerical measure of a company’s financial performance that excludes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with Generally Accepted Accounting Principles (“GAAP”) in
The orders received metric is a key performance indicator used to evaluate general sales trends and develop future operating plans. Orders received represent firm orders placed by our customers during the current quarter which are expected to be recognized as revenue during current or future quarters. The orders received metric is not intended to be presented as an alternative measure of revenue recognized in accordance with GAAP.
Forward-Looking Statements
This document may contain certain forward-looking statements about the Company, such as discussions of Company’s pricing trends, liquidity, new business results, expansion plans, anticipated expenses and planned schedules. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements generally can be identified by the use of words or phrases, including, but not limited to, “intend,” “anticipate,” “believe,” “estimate,” “project,” “target,” “plan,” “expect,” “setting up,” “beginning to,” “will,” “should,” “would,” “resume” or similar statements. We caution that forward-looking statements are subject to known and unknown risks and uncertainties that may cause the Company’s actual future results and performance to differ materially from expected results including, but not limited to, the possibility that any of the anticipated benefits of the transaction between the Company and
Conference Call / Webcast | ||
Date: | ||
Time: | ||
Dial-In #: | 1 844-602-5643 (International Calls - 1 574-990-3014) | |
Pass Code: | 7999947 |
A webcast of the live conference call may be accessed by visiting Kimball International’s Investor Relations website at www.ir.kimballinternational.com.
For those unable to participate in the live webcast, the call will be archived at www.ir.kimballinternational.com within two hours of the conclusion of the live call.
About
For over 70 years, our brands have seized opportunities to customize solutions into personalized experiences, turning ordinary spaces into meaningful places. Our family of brands includes Kimball, National, Etc., Interwoven,
Financial highlights for the third quarter ended
Condensed Consolidated Statements of Income | |||||||||||||
(Unaudited) | Three Months Ended | ||||||||||||
(Amounts in Thousands, except per share data) | |||||||||||||
$ | 180,918 | 100.0 | % | $ | 138,676 | 100.0 | % | ||||||
Cost of Sales | 125,782 | 69.5 | % | 98,843 | 71.3 | % | |||||||
Gross Profit | 55,136 | 30.5 | % | 39,833 | 28.7 | % | |||||||
Selling and Administrative Expenses | 48,783 | 26.9 | % | 44,930 | 32.4 | % | |||||||
Other General (Income) Expense | (4,523 | ) | (2.5 | %) | 0 | 0.0 | % | ||||||
Contingent Earn-Out (Gain) Loss | 2,150 | 1.2 | % | 0 | 0.0 | % | |||||||
Restructuring Expense | 1,730 | 1.0 | % | 2,617 | 1.9 | % | |||||||
Operating Income (Loss) | 6,996 | 3.9 | % | (7,714 | ) | (5.6 | %) | ||||||
Other Income (Expense), net | (1,235 | ) | (0.7 | %) | 193 | 0.2 | % | ||||||
Income (Loss) Before Taxes on Income | 5,761 | 3.2 | % | (7,521 | ) | (5.4 | %) | ||||||
Provision (Benefit) for Income Taxes | (534 | ) | (0.3 | %) | (2,992 | ) | (2.1 | %) | |||||
Net Income (Loss) | $ | 6,295 | 3.5 | % | $ | (4,529 | ) | (3.3 | %) | ||||
Earnings (Loss) Per Share of Common Stock: | |||||||||||||
Basic | $ | 0.17 | $ | (0.12 | ) | ||||||||
Diluted | $ | 0.17 | $ | (0.12 | ) | ||||||||
Average Number of Total Shares Outstanding: | |||||||||||||
Basic | 36,795 | 36,860 | |||||||||||
Diluted | 37,061 | 36,860 |
(Unaudited) | Nine Months Ended | ||||||||||||
(Amounts in Thousands, except per share data) | |||||||||||||
$ | 488,931 | 100.0 | % | $ | 422,817 | 100.0 | % | ||||||
Cost of Sales | 338,254 | 69.2 | % | 285,079 | 67.4 | % | |||||||
Gross Profit | 150,677 | 30.8 | % | 137,738 | 32.6 | % | |||||||
Selling and Administrative Expenses | 150,863 | 30.7 | % | 132,584 | 31.4 | % | |||||||
Other General (Income) Expense | (4,523 | ) | (0.9 | %) | 0 | 0.0 | % | ||||||
Contingent Earn-Out (Gain) Loss | (15,750 | ) | (3.2 | %) | 0 | 0.0 | % | ||||||
Restructuring Expense | 4,195 | 0.9 | % | 8,473 | 2.0 | % | |||||||
Goodwill Impairment | 34,118 | 7.0 | % | 0 | 0.0 | % | |||||||
Operating Income (Loss) | (18,226 | ) | (3.7 | %) | (3,319 | ) | (0.8 | %) | |||||
Other Income (Expense), net | (1,192 | ) | (0.3 | %) | 2,419 | 0.6 | % | ||||||
Income (Loss) Before Taxes on Income | (19,418 | ) | (4.0 | %) | (900 | ) | (0.2 | %) | |||||
Provision (Benefit) for Income Taxes | 650 | 0.1 | % | (919 | ) | (0.2 | %) | ||||||
Net Income (Loss) | $ | (20,068 | ) | (4.1 | %) | $ | 19 | 0.0 | % | ||||
Earnings (Loss) Per Share of Common Stock: | |||||||||||||
Basic | $ | (0.55 | ) | $ | 0.00 | ||||||||
Diluted | $ | (0.55 | ) | $ | 0.00 | ||||||||
Average Number of Total Shares Outstanding: | |||||||||||||
Basic | 36,788 | 36,932 | |||||||||||
Diluted | 36,788 | 37,529 |
Condensed Consolidated Balance Sheets | (Unaudited) 2022 |
2021 |
|||
(Amounts in Thousands) | |||||
ASSETS | |||||
Cash and cash equivalents | $ | 12,726 | $ | 24,336 | |
Receivables, net | 71,495 | 58,708 | |||
Inventories | 83,545 | 54,291 | |||
Prepaid expenses and other current assets | 30,686 | 22,012 | |||
Property and Equipment, net | 92,542 | 90,623 | |||
Right of use operating lease assets | 16,922 | 14,654 | |||
47,844 | 81,962 | ||||
Other Intangible Assets, net | 59,911 | 64,478 | |||
Deferred Tax Assets | 15,738 | 16,368 | |||
Other Assets | 17,193 | 17,163 | |||
Total Assets | $ | 448,602 | $ | 444,595 | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||
Current maturities of long-term debt | 33 | 30 | |||
Accounts payable | 70,446 | 41,537 | |||
Customer deposits | 27,595 | 24,438 | |||
Current portion of operating lease liability | 6,254 | 6,590 | |||
Dividends payable | 3,688 | 3,532 | |||
Accrued expenses | 37,081 | 39,115 | |||
Long-term debt, less current maturities | 58,046 | 40,079 | |||
Long-term operating lease liability | 14,025 | 12,536 | |||
Long-term earn-out liability | 4,440 | 20,190 | |||
Other | 14,994 | 16,878 | |||
Shareholders’ Equity | 212,000 | 239,670 | |||
Total Liabilities and Shareholders’ Equity | $ | 448,602 | $ | 444,595 |
Condensed Consolidated Statements of Cash Flows | Nine Months Ended | ||||||
(Unaudited) | |||||||
(Amounts in Thousands) | 2022 | 2021 | |||||
$ | (6,602 | ) | $ | 27,330 | |||
(10,346 | ) | (110,064 | ) | ||||
5,008 | 27,668 | ||||||
(11,940 | ) | (55,066 | ) | ||||
Cash, Cash Equivalents, and Restricted Cash at Beginning of Period | 25,727 | 92,444 | |||||
Cash, Cash Equivalents, and Restricted Cash at End of Period | $ | 13,787 | $ | 37,378 |
Reconciliation of Non-GAAP Financial Measures | |||||||||||
(Unaudited) | |||||||||||
(Amounts in Thousands, except per share data) | |||||||||||
Organic |
|||||||||||
Three Months Ended | Nine Months Ended | ||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||
$ | 180,918 | $ | 138,676 | $ | 488,931 | $ | 422,817 | ||||
Less: |
0 | 0 | 28,718 | 2,678 | |||||||
Organic |
$ | 180,918 | $ | 138,676 | $ | 460,213 | $ | 420,139 |
(1)
Adjusted Gross Profit | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Gross Profit, as reported | $ | 55,136 | $ | 39,833 | $ | 150,677 | $ | 137,738 | |||||||
Add: Pre-tax COVID vaccine incentive | 0 | 0 | 1,569 | 0 | |||||||||||
Add: Pre-tax Acquisition-related Inventory Valuation Adjustment | 48 | 247 | 253 | 289 | |||||||||||
Adjusted Gross Profit | $ | 55,184 | $ | 40,080 | $ | 152,499 | $ | 138,027 | |||||||
Adjusted Gross Profit % | 30.5 | % | 28.9 | % | 31.2 | % | 32.6 | % | |||||||
Adjusted Selling and Administrative Expense | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Selling and Administrative Expense, as reported | $ | 48,783 | $ | 44,930 | $ | 150,863 | $ | 132,584 | |||||||
Less: Pre-tax Expense Adjustment to SERP Liability | 887 | (428 | ) | 300 | (2,567 | ) | |||||||||
Less: Pre-tax CEO Transition Costs | 0 | (141 | ) | 0 | (423 | ) | |||||||||
Less: Pre-tax Acquisition-related Amortization | (1,610 | ) | (1,671 | ) | (4,830 | ) | (2,066 | ) | |||||||
Less: Pre-tax Costs of Acquisition | 0 | (47 | ) | 0 | (3,435 | ) | |||||||||
Less: Pre-tax COVID Vaccine incentive | 0 | 0 | (1,140 | ) | 0 | ||||||||||
Adjusted Selling and Administrative Expense | $ | 48,060 | $ | 42,643 | $ | 145,193 | $ | 124,093 | |||||||
Adjusted Selling and Administrative Expense % | 26.6 | % | 30.8 | % | 29.7 | % | 29.3 | % | |||||||
Adjusted Operating Income (Loss) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Operating Income (Loss), as reported | $ | 6,996 | $ | (7,714 | ) | $ | (18,226 | ) | $ | (3,319 | ) | ||||
Add: Pre-tax Restructuring Expense | 1,730 | 2,617 | 4,195 | 8,473 | |||||||||||
Add: Pre-tax Goodwill Impairment | 0 | 0 | 34,118 | 0 | |||||||||||
Add: Pre-tax Other General (Income) Expense(2) | (4,523 | ) | 0 | (4,523 | ) | 0 | |||||||||
Add: Pre-tax Expense Adjustment to SERP Liability | (887 | ) | 428 | (300 | ) | 2,567 | |||||||||
Add: Pre-tax CEO Transition Costs | 0 | 141 | 0 | 423 | |||||||||||
Add: Pre-tax Acquisition-related Amortization | 1,610 | 1,671 | 4,830 | 2,066 | |||||||||||
Add: Pre-tax Acquisition-related Inventory Valuation Adjustment | 48 | 247 | 253 | 289 | |||||||||||
Add: Pre-tax Costs of Acquisition | 0 | 47 | 0 | 3,435 | |||||||||||
Add: Pre-tax Contingent Earn-Out (Gain) Loss | 2,150 | 0 | (15,750 | ) | 0 | ||||||||||
Add: Pre-tax COVID vaccine incentive | 0 | 0 | 2,709 | 0 | |||||||||||
Adjusted Operating Income (Loss) | $ | 7,124 | $ | (2,563 | ) | $ | 7,306 | $ | 13,934 | ||||||
Adjusted Operating Income (Loss) % | 3.9 | % | (1.8) % | 1.5 | % | 3.3 | % | ||||||||
Adjusted Net Income (Loss) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Net Income (Loss), as reported | $ | 6,295 | $ | (4,529 | ) | $ | (20,068 | ) | $ | 19 | |||||
Pre-tax Restructuring Expense | 1,730 | 2,617 | 4,195 | 8,473 | |||||||||||
Tax on Restructuring Expense | (445 | ) | (673 | ) | (1,079 | ) | (2,181 | ) | |||||||
Add: After-tax Restructuring Expense | 1,285 | 1,944 | 3,116 | 6,292 | |||||||||||
Pre-tax Goodwill Impairment | 0 | 0 | 34,118 | 0 | |||||||||||
Tax on Goodwill Impairment | 0 | 0 | 0 | 0 | |||||||||||
Add: After-tax Goodwill Impairment | 0 | 0 | 34,118 | 0 | |||||||||||
Pre-tax Other General (Income) Expense(2) | (4,523 | ) | 0 | (4,523 | ) | 0 | |||||||||
Tax on Other General (Income) Expense | 1,164 | 0 | 1,164 | 0 | |||||||||||
Add: After-tax Other General (Income) Expense | (3,359 | ) | 0 | (3,359 | ) | 0 | |||||||||
Pre-tax CEO Transition Costs | 0 | 141 | 0 | 423 | |||||||||||
Tax on CEO Transition Costs | 0 | (36 | ) | 0 | (108 | ) | |||||||||
Add: After-tax CEO Transition Costs | 0 | 105 | 0 | 315 | |||||||||||
Pre-tax Acquisition-related Amortization | 1,610 | 1,671 | 4,830 | 2,066 | |||||||||||
Tax on Acquisition-related Amortization | (414 | ) | (430 | ) | (1,243 | ) | (532 | ) | |||||||
Add: After-tax Acquisition-related Amortization | 1,196 | 1,241 | 3,587 | 1,534 | |||||||||||
Pre-tax Acquisition-related Inventory Valuation Adjustment | 48 | 247 | 253 | 289 | |||||||||||
Tax on Acquisition-related Inventory Valuation Adjustment | (12 | ) | (64 | ) | (65 | ) | (75 | ) | |||||||
Add: After-tax Acquisition-related Inventory Adjustment | 36 | 183 | 188 | 214 | |||||||||||
Pre-tax Costs of Acquisition | 0 | 47 | 0 | 3,435 | |||||||||||
Tax on Costs of Acquisition | 0 | (12 | ) | 0 | (884 | ) | |||||||||
Add: After-tax Costs of Acquisition | 0 | 35 | 0 | 2,551 | |||||||||||
Pre-tax Contingent Earn-Out (Gain) Loss | 2,150 | 0 | (15,750 | ) | 0 | ||||||||||
Tax on Contingent Earn-Out (Gain) Loss | 0 | 0 | 0 | 0 | |||||||||||
Add: After-tax Contingent Earn-Out (Gain) Loss | 2,150 | 0 | (15,750 | ) | 0 | ||||||||||
Pre-tax COVID Vaccine Incentive | 0 | 0 | 2,709 | 0 | |||||||||||
Tax on COVID Vaccine Incentive | 0 | 0 | (697 | ) | 0 | ||||||||||
Add: After-tax COVID Vaccine Incentive | 0 | 0 | 2,012 | 0 | |||||||||||
Adjusted Net Income (Loss) | $ | 7,603 | $ | (1,021 | ) | $ | 3,844 | $ | 10,925 | ||||||
Adjusted Diluted Earnings (Loss) Per Share | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Diluted Earnings (Loss) Per Share, as reported | $ | 0.17 | $ | (0.12 | ) | $ | (0.55 | ) | $ | 0.00 | |||||
Add: After-tax Restructuring Expense | 0.04 | 0.05 | 0.09 | 0.17 | |||||||||||
Add: After-tax CEO Transition Costs | 0.00 | 0.00 | 0.00 | 0.01 | |||||||||||
Add: After-tax Goodwill Impairment | 0.00 | 0.00 | 0.93 | 0.00 | |||||||||||
Add: After-tax Other General (Income) Expense(2) | (0.09 | ) | 0.00 | (0.09 | ) | 0.00 | |||||||||
Add: After-tax Acquisition-related Amortization | 0.03 | 0.03 | 0.10 | 0.04 | |||||||||||
Add: After-tax Acquisition-related Inventory Valuation Adjustment | 0.00 | 0.01 | 0.01 | 0.01 | |||||||||||
Add: After-tax Costs of Acquisition | 0.00 | 0.00 | 0.00 | 0.07 | |||||||||||
Add: After-tax Contingent Earn-Out (Gain) Loss | 0.06 | 0.00 | (0.43 | ) | 0.00 | ||||||||||
Add: After-tax COVID Vaccine Incentive | 0.00 | 0.00 | 0.05 | 0.00 | |||||||||||
Adjusted Diluted Earnings (Loss) Per Share | $ | 0.21 | $ | (0.03 | ) | $ | 0.11 | $ | 0.30 |
Adjusted EBITDA | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Net Income (Loss) | $ | 6,295 | $ | (4,529 | ) | $ | (20,068 | ) | $ | 19 | |||||
Provision (Benefit) for Income Taxes | (534 | ) | (2,992 | ) | 650 | (919 | ) | ||||||||
Income (Loss) Before Taxes on Income | 5,761 | (7,521 | ) | (19,418 | ) | (900 | ) | ||||||||
Interest Expense | 390 | 177 | 922 | 263 | |||||||||||
Interest Income | (25 | ) | (59 | ) | (77 | ) | (248 | ) | |||||||
Depreciation | 3,635 | 3,708 | 10,820 | 10,836 | |||||||||||
Amortization | 2,358 | 2,510 | 7,212 | 4,212 | |||||||||||
Pre-tax Restructuring Expense | 1,730 | 2,617 | 4,195 | 8,473 | |||||||||||
Pre-tax Goodwill Impairment | 0 | 0 | 34,118 | 0 | |||||||||||
Pre-tax Other General (Income) Expense(2) | (4,523 | ) | 0 | (4,523 | ) | 0 | |||||||||
Pre-tax CEO Transition Costs | 0 | 141 | 0 | 423 | |||||||||||
Pre-tax Acquisition-related Inventory Valuation Adjustment | 48 | 247 | 253 | 289 | |||||||||||
Pre-tax Costs of Acquisition | 0 | 47 | 0 | 3,435 | |||||||||||
Pre-tax Contingent Earn-Out (Gain) Loss | 2,150 | 0 | (15,750 | ) | 0 | ||||||||||
Pre-tax COVID Vaccine Incentive | 0 | 0 | 2,709 | 0 | |||||||||||
Adjusted EBITDA | $ | 11,524 | $ | 1,867 | $ | 20,461 | $ | 26,783 | |||||||
Adjusted EBITDA % | 6.4 | % | 1.3 | % | 4.2 | % | 6.3 | % |
(2) Third quarter fiscal year 2022 Other General (Income) Expense consists of a gain realized on the sale of a warehouse totaling
Supplementary Information | |||||||||||||||
Components of Other Income, net | Three Months Ended | Nine Months Ended | |||||||||||||
(Unaudited) | |||||||||||||||
(Amounts in Thousands) | 2022 | 2021 | 2022 | 2021 | |||||||||||
Interest Income | $ | 25 | $ | 59 | $ | 77 | $ | 248 | |||||||
Interest Expense | (390 | ) | (177 | ) | (922 | ) | (263 | ) | |||||||
Gain (Loss) on Supplemental Employee Retirement Plan Investments | (887 | ) | 428 | (300 | ) | 2,567 | |||||||||
Other Non-Operating Income (Expense) | 17 | (117 | ) | (47 | ) | (133 | ) | ||||||||
Other Income (Expense), net | $ | (1,235 | ) | $ | 193 | $ | (1,192 | ) | $ | 2,419 | |||||
For additional information contact:
Telephone 812.482.1600

Source: Kimball International, Inc.